Treatments Compared for Advanced Renal Cell Carcinoma
Treatment-free survival more than twice as long for nivolumab plus ipilimumab versus sunitinib for intermediate/poor-risk patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.